-
Pravastatin Sodium: Applied Assay Workflows
2026-09-09
Build more informative cholesterol-pathway experiments with Pravastatin sodium, from macrophage LDL handling to hepatocyte viability and transporter-context studies. This workflow separates direct HMG-CoA reductase inhibition from uptake and cytotoxicity effects, improving interpretation across cell models.
-
Calpeptin: Calpain Inhibitor for Fibrosis Research
2026-09-09
Calpeptin is a nanomolar calpain inhibitor used to study calcium-dependent cysteine protease signaling. Product data report activity against human calpain 1 and reductions in fibrotic and inflammatory markers in lung fibroblast and mouse pulmonary fibrosis models.
-
MK-571 (L-660,711) Assay Workflow Guide
2026-09-08
MK-571 (L-660,711) supports two complementary research questions: cysteinyl leukotriene receptor 1 blockade in airway inflammation and ABCC1/MRP1-linked transport in macrophage chemoprotection. This workflow guide shows how to separate those activities, control DMSO and precipitation risks, and translate receptor pharmacology into reproducible inflammation assays.
-
Oteseconazole (VT-1161) Candida Assay Workflows
2026-09-08
Oteseconazole (VT-1161) combines potent fungal CYP51 inhibition with a practical profile for Candida susceptibility, resistance, and mechanism-focused studies. This workflow shows how to convert its formulation properties and published clinical-isolate screening principles into reproducible MIC, MFC, and comparative assays.
-
Danazol as a Translational Endocrine Model
2026-09-07
Danazol is more than a synthetic androgenic steroid: it is a mechanistically rich perturbation tool for studying steroidogenesis, hypothalamic–pituitary–gonadal signaling, precocious puberty, and prostate cancer research. This article connects product selection with model design, evidence interpretation, and translational strategy.
-
TH287 Radiosensitizes CRPC Cells to Ionizing Radiation
2026-09-07
The reference study identifies a timing-dependent radiosensitization strategy in PC-3 and DU-145 castration-resistant prostate cancer models, with TH287 producing the strongest combination effect when ionizing radiation was applied 12 hours after drug exposure. The findings connect MTH1 inhibition with reduced survival, increased apoptosis, and cell-cycle disruption, while also highlighting the need for clonogenic, normal-cell, and in vivo validation.
-
Fluconazole: Mechanism, Benchmarks, and Workflows
2026-09-05
Fluconazole is a fungal cytochrome P450 enzyme 14α-demethylase inhibitor that suppresses ergosterol biosynthesis. This evidence-focused guide defines its research applications, solvent and storage parameters, susceptibility-testing value, and limits in resistant Candida models.
-
Oteseconazole (VT-1161) Research Workflows
2026-09-04
Build reproducible Candida susceptibility, resistance, biofilm, and ergosterol-pathway assays with Oteseconazole (VT-1161). This workflow distinguishes validated product performance from exploratory conditions, helping researchers exploit potent CYP51 inhibition without overextending conclusions to Aspergillus or clinical outcomes.
-
S63845 MCL1 Inhibitor: Workflow & Troubleshooting
2026-09-04
Build reproducible apoptosis assays around S63845, from DMSO handling and dose-response design to mitochondrial pathway confirmation. The workflow also shows how to extend single-agent studies into mechanistically informed combinations involving death-ligand signaling, gemcitabine, and c-FLIPL targeting.
-
Itraconazole B2104 for Reliable Cell Assays
2026-09-03
Itraconazole (SKU B2104) offers a practical, data-grounded framework for antifungal, cell viability, and drug-interaction experiments. This scenario-based guide addresses solubility, biofilm resistance, assay controls, concentration interpretation, and vendor selection using product specifications and recent Candida research.
-
Oltipraz Workflows for MASLD Nrf2 Research
2026-09-03
Oltipraz provides a defined Nrf2-activating tool for connecting phase II enzyme induction with autophagy and ferroptosis assays in liver disease models. This workflow shows how to distinguish direct redox-pathway activity from broader effects reported for Qushi Huoxue ointment while improving dosing, controls, and troubleshooting.
-
CX-4945 (Silmitasertib): CK2 Cancer Research
2026-09-02
CX-4945, also called Silmitasertib, is an ATP-competitive CK2 inhibitor used to investigate CK2-dependent signaling, apoptosis, and context-specific cell-cycle control. Product and peer-reviewed evidence support its use as a mechanistic research tool, but cellular and xenograft findings do not establish a universal clinical anticancer effect.
-
Exemestane: From Mechanism to Translation
2026-09-02
A translational framework for using Exemestane as a steroidal aromatase inhibitor, connecting irreversible enzyme inactivation with model selection, assay design, biomarker strategy, and breast cancer research decisions.
-
PP2A, Autophagy, and Candida Biofilm Drug Resistance
2026-09-01
A 2025 study identifies PP2A-dependent phosphorylation of Atg13 and activation of Atg1 as a regulatory route linking autophagy to Candida albicans biofilm formation and antifungal resistance. Its mutant, pharmacologic, oxidative-stress, imaging, and mouse oral-infection experiments suggest that disrupting this pathway may improve antifungal responses, although the findings remain specific to C. albicans biofilms and the tested infection model.
-
Sulfaphenazole Restores Vasodilation in Diabetic Mice
2026-09-01
This study identified CYP 2C-derived oxidative stress as a pharmacologically tractable contributor to endothelial dysfunction in db/db mice. Sulfaphenazole restored acetylcholine-dependent vasodilation, reduced systemic oxidative stress, and increased nitric oxide bioavailability without lowering plasma glucose, linking cytochrome P450 activity to vascular injury independently of glycemic control.